Report Detail

Request for Sample of this report

Pharma & Healthcare Global Meningococcal Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

  • RnM4723621
    • |
  • 21 July, 2026
    • |
  • Global
    • |
  • 142 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Meningococcal Vaccine market size was valued at US$ 4257 million in 2025 and is forecast to a readjusted size of US$ 6544 million by 2032 with a CAGR of 6.2% during review period.
Meningococcal vaccines are preventive biological products designed to generate active immunity against invasive disease caused by Neisseria meningitidis. They are used in routine childhood and adolescent immunization, preventive campaigns, outbreak response, travel vaccination and the protection of medically or occupationally exposed populations. Current marketed serogroup configurations include monovalent MenA, MenB and MenC vaccines; bivalent MenAC and MenBC vaccines; trivalent MenACW vaccines; quadrivalent MenACWY vaccines; and pentavalent MenABCWY and MenACWYX vaccines. MenABCWY is an emerging commercial segment represented by Pfizer’s Penbraya and GSK’s Penmenvy, while MenACWYX is represented by Serum Institute of India’s MenFive. Commercial technology platforms comprise plain polysaccharide vaccines, conjugate vaccines, recombinant protein vaccines and multi-platform products combining conjugate, recombinant protein or outer-membrane-vesicle components.
Upstream supply depends on qualified meningococcal strains, capsular polysaccharides, recombinant antigens, outer-membrane-vesicle antigens, carrier proteins, stabilizers, sterile containers and validated cold-chain packaging. Manufacturing remains concentrated because biological consistency, aseptic processing, analytical comparability, regulatory approval and lot-release testing must be maintained over long production cycles. Downstream purchasers include ministries of health, national immunization programs, international procurement organizations, hospitals, vaccination clinics, pharmacies, travel-health centers, military organizations, universities and occupational-health providers. Public demand is commonly supplied through annual tenders, multi-year framework agreements, stockpile contracts and emergency procurement, while commercial vaccines are distributed through direct supply agreements and specialist health-care channels. Industry gross margin is estimated at approximately 68%, supported by premium-priced conjugate, MenB and pentavalent products but moderated by lower-price public-health procurement.
In the current market, global production of meningococcal vaccines is around 197 million doses, with an average selling price of about 21.00 USD per dose on an EXW basis. Value is more concentrated than physical volume because commercial MenB, MenACWY and MenABCWY vaccines command substantially higher prices than polysaccharide and public-procurement products used extensively in China and the African meningitis belt. The top five suppliers control approximately 84% of global revenue. GSK leads through Bexsero, Menveo and Penmenvy, followed by Sanofi and Pfizer. Serum Institute of India has an important position in African public-health procurement through MenAfriVac and MenFive, although its revenue share is lower than its dose share. China has a broader manufacturing base spanning MenA, MenAC and MenACWY products. North America is the largest value market, followed by Europe, while China and Africa account for a disproportionately large share of global dose volume.
During 2026–2032, demand is expected to move further from plain polysaccharide vaccines toward conjugate and broader multivalent products. MenFive adoption should expand protection against serogroups A, C, W, Y and X in the African meningitis belt. MenABCWY products may simplify immunization for adolescents and high-risk populations currently requiring separate MenACWY and MenB vaccinations. However, the pentavalent category will remain concentrated in a small number of manufacturers because of its complex antigen composition, clinical requirements and multi-component presentation. Regulatory authorities will continue to emphasize lot consistency, age-specific effectiveness, post-marketing surveillance and long-term supply reliability. Public tenders will maintain pricing pressure, while wider reimbursement of MenB and pentavalent vaccines should support gradual ASP growth. Key bottlenecks include long biological production and release cycles, limited antigen and carrier-protein capacity, sterile fill-finish constraints, cold-chain requirements and irregular government procurement. Changes in circulating serogroups may also require revisions to national schedules and stockpile composition.
This report is a detailed and comprehensive analysis for global Meningococcal Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Vaccine Platform and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Meningococcal Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (million Dose), and average selling prices (US$/Dose), 2021-2032
Global Meningococcal Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (million Dose), and average selling prices (US$/Dose), 2021-2032
Global Meningococcal Vaccine market size and forecasts, by Vaccine Platform and by Application, in consumption value ($ Million), sales quantity (million Dose), and average selling prices (US$/Dose), 2021-2032
Global Meningococcal Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (million Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Meningococcal Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Meningococcal Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Sanofi, Pfizer, Serum Institute of India, CanSino Biologics, Yuxi Walvax Biotechnology, Beijing Zhifei Lvzhu Biopharmaceutical, China National Biotec Group, Fundação Oswaldo Cruz, Fundação Ezequiel Dias, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Meningococcal Vaccine market is split by Vaccine Platform and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Vaccine Platform, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Vaccine Platform
Plain Polysaccharide Vaccines
Conjugate Vaccines
Recombinant Protein Vaccines
Multi-Platform Vaccines
Market segment by Serogroup Coverage
MenA Vaccines
MenB Vaccines
MenC Vaccines
MenAC Vaccines
MenBC Vaccines
MenACW Vaccines
MenACWY Vaccines
MenABCWY Vaccines
MenACWYX Vaccines
Market segment by Presentation
Single-Dose Liquid
Multi-Dose Liquid
Single-Dose Lyophilized
Multi-Dose Lyophilized
Multi-Component Kit
Market segment by Application
Routine Pediatric Immunization
Routine Adolescent Immunization
Preventive Mass Campaigns
Outbreak Response
High-Risk Clinical Immunization
Travel Immunization
Institutional Immunization
Occupational Immunization
Catch-Up Immunization
Other Immunization
Major players covered
GSK
Sanofi
Pfizer
Serum Institute of India
CanSino Biologics
Yuxi Walvax Biotechnology
Beijing Zhifei Lvzhu Biopharmaceutical
China National Biotec Group
Fundação Oswaldo Cruz
Fundação Ezequiel Dias
Instituto Finlay de Vacunas
PT Bio Farma
Hualan Biological Bacterin
Chengdu Olymvax Biopharmaceuticals
Royal Wuxi Bio-Pharmaceutical
AIM Persistence Biopharmaceutical
NPO Microgen
Incepta Vaccine
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Meningococcal Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Meningococcal Vaccine, with price, sales quantity, revenue, and global market share of Meningococcal Vaccine from 2021 to 2026.
Chapter 3, the Meningococcal Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Meningococcal Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Vaccine Platform and by Application, with sales market share and growth rate by Vaccine Platform, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Meningococcal Vaccine market forecast, by regions, by Vaccine Platform, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Meningococcal Vaccine.
Chapter 14 and 15, to describe Meningococcal Vaccine sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Vaccine Platform
    • 1.3.1 Overview: Global Meningococcal Vaccine Consumption Value by Vaccine Platform: 2021 Versus 2025 Versus 2032
    • 1.3.2 Plain Polysaccharide Vaccines
    • 1.3.3 Conjugate Vaccines
    • 1.3.4 Recombinant Protein Vaccines
    • 1.3.5 Multi-Platform Vaccines
  • 1.4 Market Analysis by Serogroup Coverage
    • 1.4.1 Overview: Global Meningococcal Vaccine Consumption Value by Serogroup Coverage: 2021 Versus 2025 Versus 2032
    • 1.4.2 MenA Vaccines
    • 1.4.3 MenB Vaccines
    • 1.4.4 MenC Vaccines
    • 1.4.5 MenAC Vaccines
    • 1.4.6 MenBC Vaccines
    • 1.4.7 MenACW Vaccines
    • 1.4.8 MenACWY Vaccines
    • 1.4.9 MenABCWY Vaccines
    • 1.4.10 MenACWYX Vaccines
  • 1.5 Market Analysis by Presentation
    • 1.5.1 Overview: Global Meningococcal Vaccine Consumption Value by Presentation: 2021 Versus 2025 Versus 2032
    • 1.5.2 Single-Dose Liquid
    • 1.5.3 Multi-Dose Liquid
    • 1.5.4 Single-Dose Lyophilized
    • 1.5.5 Multi-Dose Lyophilized
    • 1.5.6 Multi-Component Kit
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Meningococcal Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Routine Pediatric Immunization
    • 1.6.3 Routine Adolescent Immunization
    • 1.6.4 Preventive Mass Campaigns
    • 1.6.5 Outbreak Response
    • 1.6.6 High-Risk Clinical Immunization
    • 1.6.7 Travel Immunization
    • 1.6.8 Institutional Immunization
    • 1.6.9 Occupational Immunization
    • 1.6.10 Catch-Up Immunization
  • 1.7 Global Meningococcal Vaccine Market Size & Forecast
    • 1.7.1 Global Meningococcal Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Meningococcal Vaccine Sales Quantity (2021-2032)
    • 1.7.3 Global Meningococcal Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 GSK
    • 2.1.1 GSK Details
    • 2.1.2 GSK Major Business
    • 2.1.3 GSK Meningococcal Vaccine Product and Services
    • 2.1.4 GSK Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 GSK Recent Developments/Updates
  • 2.2 Sanofi
    • 2.2.1 Sanofi Details
    • 2.2.2 Sanofi Major Business
    • 2.2.3 Sanofi Meningococcal Vaccine Product and Services
    • 2.2.4 Sanofi Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sanofi Recent Developments/Updates
  • 2.3 Pfizer
    • 2.3.1 Pfizer Details
    • 2.3.2 Pfizer Major Business
    • 2.3.3 Pfizer Meningococcal Vaccine Product and Services
    • 2.3.4 Pfizer Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Pfizer Recent Developments/Updates
  • 2.4 Serum Institute of India
    • 2.4.1 Serum Institute of India Details
    • 2.4.2 Serum Institute of India Major Business
    • 2.4.3 Serum Institute of India Meningococcal Vaccine Product and Services
    • 2.4.4 Serum Institute of India Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Serum Institute of India Recent Developments/Updates
  • 2.5 CanSino Biologics
    • 2.5.1 CanSino Biologics Details
    • 2.5.2 CanSino Biologics Major Business
    • 2.5.3 CanSino Biologics Meningococcal Vaccine Product and Services
    • 2.5.4 CanSino Biologics Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 CanSino Biologics Recent Developments/Updates
  • 2.6 Yuxi Walvax Biotechnology
    • 2.6.1 Yuxi Walvax Biotechnology Details
    • 2.6.2 Yuxi Walvax Biotechnology Major Business
    • 2.6.3 Yuxi Walvax Biotechnology Meningococcal Vaccine Product and Services
    • 2.6.4 Yuxi Walvax Biotechnology Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Yuxi Walvax Biotechnology Recent Developments/Updates
  • 2.7 Beijing Zhifei Lvzhu Biopharmaceutical
    • 2.7.1 Beijing Zhifei Lvzhu Biopharmaceutical Details
    • 2.7.2 Beijing Zhifei Lvzhu Biopharmaceutical Major Business
    • 2.7.3 Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Product and Services
    • 2.7.4 Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Beijing Zhifei Lvzhu Biopharmaceutical Recent Developments/Updates
  • 2.8 China National Biotec Group
    • 2.8.1 China National Biotec Group Details
    • 2.8.2 China National Biotec Group Major Business
    • 2.8.3 China National Biotec Group Meningococcal Vaccine Product and Services
    • 2.8.4 China National Biotec Group Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 China National Biotec Group Recent Developments/Updates
  • 2.9 Fundação Oswaldo Cruz
    • 2.9.1 Fundação Oswaldo Cruz Details
    • 2.9.2 Fundação Oswaldo Cruz Major Business
    • 2.9.3 Fundação Oswaldo Cruz Meningococcal Vaccine Product and Services
    • 2.9.4 Fundação Oswaldo Cruz Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Fundação Oswaldo Cruz Recent Developments/Updates
  • 2.10 Fundação Ezequiel Dias
    • 2.10.1 Fundação Ezequiel Dias Details
    • 2.10.2 Fundação Ezequiel Dias Major Business
    • 2.10.3 Fundação Ezequiel Dias Meningococcal Vaccine Product and Services
    • 2.10.4 Fundação Ezequiel Dias Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Fundação Ezequiel Dias Recent Developments/Updates
  • 2.11 Instituto Finlay de Vacunas
    • 2.11.1 Instituto Finlay de Vacunas Details
    • 2.11.2 Instituto Finlay de Vacunas Major Business
    • 2.11.3 Instituto Finlay de Vacunas Meningococcal Vaccine Product and Services
    • 2.11.4 Instituto Finlay de Vacunas Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Instituto Finlay de Vacunas Recent Developments/Updates
  • 2.12 PT Bio Farma
    • 2.12.1 PT Bio Farma Details
    • 2.12.2 PT Bio Farma Major Business
    • 2.12.3 PT Bio Farma Meningococcal Vaccine Product and Services
    • 2.12.4 PT Bio Farma Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 PT Bio Farma Recent Developments/Updates
  • 2.13 Hualan Biological Bacterin
    • 2.13.1 Hualan Biological Bacterin Details
    • 2.13.2 Hualan Biological Bacterin Major Business
    • 2.13.3 Hualan Biological Bacterin Meningococcal Vaccine Product and Services
    • 2.13.4 Hualan Biological Bacterin Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Hualan Biological Bacterin Recent Developments/Updates
  • 2.14 Chengdu Olymvax Biopharmaceuticals
    • 2.14.1 Chengdu Olymvax Biopharmaceuticals Details
    • 2.14.2 Chengdu Olymvax Biopharmaceuticals Major Business
    • 2.14.3 Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Product and Services
    • 2.14.4 Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Chengdu Olymvax Biopharmaceuticals Recent Developments/Updates
  • 2.15 Royal Wuxi Bio-Pharmaceutical
    • 2.15.1 Royal Wuxi Bio-Pharmaceutical Details
    • 2.15.2 Royal Wuxi Bio-Pharmaceutical Major Business
    • 2.15.3 Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Product and Services
    • 2.15.4 Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Royal Wuxi Bio-Pharmaceutical Recent Developments/Updates
  • 2.16 AIM Persistence Biopharmaceutical
    • 2.16.1 AIM Persistence Biopharmaceutical Details
    • 2.16.2 AIM Persistence Biopharmaceutical Major Business
    • 2.16.3 AIM Persistence Biopharmaceutical Meningococcal Vaccine Product and Services
    • 2.16.4 AIM Persistence Biopharmaceutical Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 AIM Persistence Biopharmaceutical Recent Developments/Updates
  • 2.17 NPO Microgen
    • 2.17.1 NPO Microgen Details
    • 2.17.2 NPO Microgen Major Business
    • 2.17.3 NPO Microgen Meningococcal Vaccine Product and Services
    • 2.17.4 NPO Microgen Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 NPO Microgen Recent Developments/Updates
  • 2.18 Incepta Vaccine
    • 2.18.1 Incepta Vaccine Details
    • 2.18.2 Incepta Vaccine Major Business
    • 2.18.3 Incepta Vaccine Meningococcal Vaccine Product and Services
    • 2.18.4 Incepta Vaccine Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Incepta Vaccine Recent Developments/Updates

3 Competitive Environment: Meningococcal Vaccine by Manufacturer

  • 3.1 Global Meningococcal Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Meningococcal Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global Meningococcal Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Meningococcal Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Meningococcal Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Meningococcal Vaccine Manufacturer Market Share in 2025
  • 3.5 Meningococcal Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Meningococcal Vaccine Market: Region Footprint
    • 3.5.2 Meningococcal Vaccine Market: Company Product Type Footprint
    • 3.5.3 Meningococcal Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Meningococcal Vaccine Market Size by Region
    • 4.1.1 Global Meningococcal Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Meningococcal Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global Meningococcal Vaccine Average Price by Region (2021-2032)
  • 4.2 North America Meningococcal Vaccine Consumption Value (2021-2032)
  • 4.3 Europe Meningococcal Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Meningococcal Vaccine Consumption Value (2021-2032)
  • 4.5 South America Meningococcal Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Meningococcal Vaccine Consumption Value (2021-2032)

5 Market Segment by Vaccine Platform

  • 5.1 Global Meningococcal Vaccine Sales Quantity by Vaccine Platform (2021-2032)
  • 5.2 Global Meningococcal Vaccine Consumption Value by Vaccine Platform (2021-2032)
  • 5.3 Global Meningococcal Vaccine Average Price by Vaccine Platform (2021-2032)

6 Market Segment by Application

  • 6.1 Global Meningococcal Vaccine Sales Quantity by Application (2021-2032)
  • 6.2 Global Meningococcal Vaccine Consumption Value by Application (2021-2032)
  • 6.3 Global Meningococcal Vaccine Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Meningococcal Vaccine Sales Quantity by Vaccine Platform (2021-2032)
  • 7.2 North America Meningococcal Vaccine Sales Quantity by Application (2021-2032)
  • 7.3 North America Meningococcal Vaccine Market Size by Country
    • 7.3.1 North America Meningococcal Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Meningococcal Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Meningococcal Vaccine Sales Quantity by Vaccine Platform (2021-2032)
  • 8.2 Europe Meningococcal Vaccine Sales Quantity by Application (2021-2032)
  • 8.3 Europe Meningococcal Vaccine Market Size by Country
    • 8.3.1 Europe Meningococcal Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Meningococcal Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Meningococcal Vaccine Sales Quantity by Vaccine Platform (2021-2032)
  • 9.2 Asia-Pacific Meningococcal Vaccine Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Meningococcal Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Meningococcal Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Meningococcal Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Meningococcal Vaccine Sales Quantity by Vaccine Platform (2021-2032)
  • 10.2 South America Meningococcal Vaccine Sales Quantity by Application (2021-2032)
  • 10.3 South America Meningococcal Vaccine Market Size by Country
    • 10.3.1 South America Meningococcal Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Meningococcal Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Meningococcal Vaccine Sales Quantity by Vaccine Platform (2021-2032)
  • 11.2 Middle East & Africa Meningococcal Vaccine Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Meningococcal Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Meningococcal Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Meningococcal Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Meningococcal Vaccine Market Drivers
  • 12.2 Meningococcal Vaccine Market Restraints
  • 12.3 Meningococcal Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Meningococcal Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Meningococcal Vaccine
  • 13.3 Meningococcal Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Meningococcal Vaccine Typical Distributors
  • 14.3 Meningococcal Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Meningococcal Vaccine. Industry analysis & Market Report on Meningococcal Vaccine is a syndicated market report, published as Global Meningococcal Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Meningococcal Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo